Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Wright Reports
$75.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

PDL BioPharma Inc Issues Q3 2013 Revenue Guidance In Line With Analysts' Estimates


Monday, 9 Sep 2013 07:00am EDT 

PDL BioPharma Inc announced that for third quarter of 2013, it expects revenue of approximately $97 million, as compared with actual revenue of $85 million for the third quarter of 2012, an approximate 14% increase. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $98 million for third quarter of 2013. 

Company Quote

7.51
0.04 +0.54%
4:00pm EDT